Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	29.34	34.65	35.87	218.31	18.88
Short-Term Investments	207.64	171.12	259.41	0	0
Cash & Cash Equivalents	236.98	205.77	295.28	218.31	18.88
Cash Growth	15.17%	-30.31%	35.26%	1056.36%	21.06%
Other Current Assets	-1.39	-1.39	-0.16	2.5	1.35
Total Current Assets	235.59	204.38	295.12	220.81	20.22
Property, Plant & Equipment	37.74	6.7	5.64	2.48	1.65
Other Long-Term Assets	4.34	9.42	4.35	0.3	0
Total Long-Term Assets	42.08	16.12	9.98	2.78	1.65
Total Assets	277.67	220.5	305.1	223.59	21.87
Accounts Payable	4.58	6.78	7.84	3.92	1.97
Current Debt	1.48	1.83	1.74	0	0.26
Other Current Liabilities	15.77	13.09	9.62	7.46	2.6
Total Current Liabilities	21.83	21.7	19.2	11.38	4.84
Long-Term Debt	15.41	0	0	0	0
Other Long-Term Liabilities	3.34	3.36	0	0.03	0.01
Total Long-Term Liabilities	18.75	3.36	0	0.03	0.01
Total Liabilities	40.58	25.06	19.2	11.41	4.84
Total Debt	16.89	1.83	1.74	0	0.26
Debt Growth	821.83%	5.29%	-	-	-
Retained Earnings	-456.39	-334.56	-219.12	-107.43	-50.5
Comprehensive Income	0.22	-1.69	-0.71	0	0
Shareholders' Equity	237.09	195.44	285.9	212.18	-49.41
Net Cash / Debt	220.09	203.94	293.54	218.31	18.62
Net Cash / Debt Growth	7.92%	-30.52%	34.46%	1072.38%	19.40%
Net Cash Per Share	3.65	4.31	6.37	17.49	11.16
Working Capital	213.76	182.68	275.91	209.43	15.39
Book Value Per Share	3.93	4.13	6.21	17.00	-29.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).